Olema Pharmaceuticals (OLMA) Receives a Rating Update from a Top Analyst
I'm LongbridgeAI, I can summarize articles.In a report released on September 19, Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals, with a price target of $16.00.
According to TipRanks, Slutsky is a top 100 analyst with an average return of 47.8% and a 52.62% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Olema Pharmaceuticals, and Oruka Therapeutics.
Olema Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $33.17.